• Japanese
  • Korean
  • Chinese
Cover Image

Molecular Diagnostics

Product Description

This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following Product Segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 103 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Life Technologies Corporation, Celera, Biomerieux, CytoCore Inc., ELITech Group, GE Healthcare, Genzyme Corporation, Hologic, Inc., Laboratory Corporation of America Holdings, MiraiBio, Inc., Novartis Diagnostics, QIAGEN N. V, Quest Diagnostics, Inc., Roche Diagnostics, Siemens Healthcare Diagnostics, and Tecan Group Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definitions and Scope of Study

  • Infectious Diseases Testing
  • Pharmacogenomics
  • Cancer Screening

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Global Market Outlook
  • Molecular Diagnostics - A Quick Primer
  • Molecular Diagnostics - The Fastest Growing Medical Diagnostic Technology
  • Key Challenges to Growth
  • Current and Future analysis
  • US and Europe - Leaders in Molecular Diagnostics Adoption
  • Developing Nations Offer Immense Potential
  • Going Strong...
  • New Applications Hold Promising Potential
  • Infectious Disease Testing Drives the Diagnostics Market
  • The Future in Store

2. A REVIEW OF MEDICAL DIAGNOSTICS MARKET

  • Clinical Diagnostics Industry - Trends and Tendencies
    • Table 1: Worldwide In Vitro Diagnostics (IVD) Market (2010) - Market Share Breakdown by Value Sales for Roche Diagnostics, Abbott Laboratories, Siemens, J&J, Beckman Coulter, bioMerieux, and Others (includes corresponding Graph/Chart)
    • Table 2: Global In-Vitro Diagnostics (IVD) Market (2010) - Value Sales (in US$ Billion) and Percentage Share Breakdown for Point of Care, Immunity Tests, Clinical Chemistry, Nucleic Acid Tests, Histology/Cytology, Microbiology, Haematology and Others (includes corresponding Graph/Chart)
  • Diagnostic Tests - Classification
  • Nucleic Acid Diagnostics Market - An Overview
  • Molecular Diagnostics - Growth Drivers
  • Molecular Diagnostics - A Replacement and Enabling Technology
  • Molecular Diagnostics for Lymphoid Malignancies

3. COMPETITIVE DYNAMICS IN THE MOLECULAR DIAGNOSTICS MARKET

  • Competitive Landscape
    • Table 3: Worldwide Molecular Diagnostics Market (2011) - Percentage Share Breakdown by Value Sales for Roche Diagnostics, Qiagen, Abbott, Hologic (Gen-Probe), Siemens, Becton, Dickinson & Company and Others (includes corresponding Graph/Chart)
  • Key Players and Their Technologies
  • The Top Tier
  • Mid-Sized and Small Companies
  • New Entrants Eye Unmet Needs

4. MARKET TRENDS & ISSUES

  • Market Consolidations on the Way to Integrate in Vivo and in Vitro Diagnostics
  • Global Molecular Diagnostics on a High Growth Curve
  • Automation Driving Global Market
  • Molecular Diagnostics: Marking the Convergence of Numerous Technologies
  • MDx Market for Infectious Diseases Zooming Ahead
  • Aging Population, Disease Incidence - Fundamental Drivers of Growth
  • Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market
  • Towards Tailoring the Right Treatment for the Right Disease
  • Limited Reimbursements by Third Party Payers - A Stumbling Block
  • Disease-Specific Molecular Diagnostics to Deliver Improved Clinical Outcomes
  • Molecular Diagnostics and Intellectual Property
  • Business Opportunities in the Offing
  • Medical Training and Practice Challenges
  • Hurdles All the Way for Companies Eyeing Molecular Diagnostics
  • Product Marketing - Key to Commercial Success
  • Integration of Molecular Diagnostics into Therapeutics
  • Molecular Diagnostics - Moving from Centralization to Decentralization
  • Migrating to Decentralized Format
  • Going Ahead with Decentralization

5. PRODUCT & TECHNOLOGY OVERVIEW

  • Molecular Diagnostics - Definition & Scope
  • Molecular Diagnostics - Impact on Healthcare
  • Utility of Molecular Diagnostic Tests
  • Background of Molecular Diagnostics
  • Major Molecular Diagnostics Products
  • Major Test Launches in Molecular Diagnostics in the Recent Past
  • Unabated Developments in Molecular Diagnostics Technology
  • Signal Amplification Technologies
    • PCR - New Developments
      • Major Applications of Real-Time PCR
    • Quantitative Real-Time PCR for Molecular Diagnostics
    • Signal Detection and Quantification
    • Quantitative Real-Time RT-PCR Analysis
      • Applications of Quantitative Real-Time PCR Analysis
      • Viral Detection and Viral-Load Monitoring
      • Sensitive Detection of Infectious Disease Agents
      • Predisposition Testing
    • Non-PCR Methods
    • Other Signal Amplification Technologies
  • DNA Probe Based Products
    • Direct Detection of Specific Nucleic Acid Sequences
    • Nucleic Acid Amplification and Detection
    • DNA Sequencing and Gene Detection
    • Arrays of Immobilized Probes (DNA Chips) in Gene Detection
  • RNA Diagnostics
  • Complementary Molecular Diagnostic Technologies
    • Fluorescent In-Situ Hybridization (FISH)
    • DNA Biochips / Microarrays
    • Biosensors
    • Proteomic Technologies for Molecular Diagnostics
    • Nanotechnology for Molecular Diagnostics
  • Technologies on the Anvil
    • Haplotype Analysis - A Distant Possibility
    • Chronic Multi-Gene Defects Now Diagnosable

6. AN INSIGHT INTO APPLICATIONS OF MOLECULAR DIAGNOSTICS

  • Infectious Diseases Testing
  • Activity in the Field
  • Identifying Multidrug Resistance
  • Infectious Disease Treatment Monitoring
  • Other Infectious Diseases Applications
  • Genetic Disease Testing Applications
  • Pharmacogenomics - Prognosis Based on Genomics
  • Cancer Screening & Diagnosis
  • Molecular Tests Lead the Way for Cancer IVD Market Growth
  • Other Testing Applications

7. RECENT INDUSTRY ACTIVITY

  • Trovagene Acquires MultiGEN's Clinical Laboratory Assets
  • Qiagen Acquires Intelligent Bio-Systems
  • Siemens Inks Agreements with Tocagen and ViiV Healthcare to Develop Companion Tests
  • HTG Molecular Diagnostics Collaborates with Sanofi US
  • DaAn Gene and Life Technologies Form Joint Venture
  • Exosome Diagnostics and Life Technologies Ink Agreement
  • GE Healthcare Acquires SeqWright
  • Phthisis Diagnostics Expands its Distribution Network
  • Luminex to Acquire GenturaDx
  • Phthisis Diagnostics Inks Distribution Agreement with Genetix Biotech Asia
  • Life Technologies Acquires Navigenics
  • Abbott to Join Forces with Merck
  • Signal Genetics to Acquire ChipDX LLC
  • Quest Diagnostics Acquires S.E.D. Medical Laboratories
  • Hologic Acquires Gen-Probe
  • Accelerate Brain Cancer Cure Joins Hands with Exosome Diagnostics
  • QIAGEN Collaborates with Cardinal Health
  • LabCorp Acquires MEDTOX
  • Genzyme Inks Agreement with Veracyte to Market Afirma Thyroid FNA Analysis Solution
  • Celera Enters into Distribution Agreement with Abbott
  • Sanofi-Aventis Acquires Genzyme
  • Genzyme Divests Diagnostic Products Business to Sekisui Chemical
  • Fortis Healthcare's Offshore Subsidiary Acquires Controlling Stake in RadLink
  • Agilent Technologies Inks Partnership Agreement with Integrated Diagnostics
  • Genzyme to Divest Pharmaceutical Intermediates Business to ICIG's Affiliate
  • Hologic Acquires Interlace Medical
  • Applied BioCode Inks License and Supply Agreement with Hologic
  • WuXi AppTec Partners with Qiagen
  • OCM Acquisition Takes over Orchid Cellmark
  • Modern Mobility Aids to Take Over LumiGene Technologies
  • AmerisourceBergen Takes over Premier Source
  • QIAGEN Acquires Cellestis
  • QIAGEN Signs Agreement to Acquire Majority Interest in Ipsogen
  • Novartis to Acquire Genoptix
  • Vermillion Concludes Purchase of Correlogic's Ovarian Cancer Diagnostics Business
  • VitaPath Genetics and Alere Enter into Strategic Partnership for Molecular Diagnostics
  • Mingyuan Medicare to Purchase 70% Stake in Yuangi Bio
  • Quest Diagnostics Acquires Athena Diagnostics
  • Luminex Takes Over Eragen Biosciences
  • Life Technologies Enters into Distribution Commercial Agreement for Quidel Assays
  • BD and Diagenode Announce Agreement
  • Gamma-Dynacare Buys Warnex Medical Laboratories
  • OraSure Technologies to Takeover DNA Genotek
  • Hologic Takes Over TCT International
  • Affymetrix to Purchase eBioscience
  • Sequenom Enters into Licensing Partnership with LifeCodexx
  • LABSCO Inks Agreement with Cepheid
  • Abbott to Expand GSK Agreement for Cancer Companion Diagnostic Test
  • IntegenX Signs Distribution Agreement with Promega for RapidHIT Human Identification System
  • BD Diagnostics Partners with Biodiversity for BD MAX Molecular Diagnostic Assays
  • bioMerieux Acquires ARGENE
  • Caliper Partners with Seegene to Expand Diagnostic Tests
  • Enzo Clinical Labs Enters into Agreement with IncellDx
  • Akonni and Seegene Ink Licensing Agreement
  • Tecan Signs OEM Agreement with Major Diagnostics Company
  • Tecan Inks License and Collaboration Agreement with Enigma
  • Myriad Genetics Secures Option to Buy Crescendo Bioscience
  • PerkinElmer Takes Over chemagen Biopolymer- Technologie AG
  • Mayo Clinic Enters into Agreement with Rheonix
  • Qiagen and Epigenomics Ink Option Agreement

8. INDUSTRY ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER

  • ExonHit Therapeutics to Acquire RedPath Integrated Pathology
  • Life Technologies Acquires AcroMetrix of Benicia
  • Bar Harbor BioTechnology Establishes New Division
  • SIRS-Lab Partners with Analytik Jena
  • QIAGEN Enters into a Partnership with Genome Diagnostics
  • IncellDx Enters into Supply Contract with Accuri
  • BioMerieux Partners with Knome
  • Caliper Enters into an Agreement with Access Genetics
  • Debiopharm Group Forms Partnership with Biocartis
  • AdnaGen AG Enters into a Contract with TATAA Molecular Diagnostics
  • Roche Diagnostics Enters into Partnership with CapitalBio
  • Epigenomics Signs Distribution Agreement with Epi proColon
  • Genomic Health Selects IDBS to Provide Tools for Clinical Research
  • TriLink BioTechnologies Signs Agreement with Biofortuna
  • Pathwork Diagnostics Enters into Partnership with Novartis
  • Affymetrix Signs Agreement with Signature Diagnostics
  • Knome and bioMerieux Ink Exclusive Strategic Agreement
  • GenMark Receives License to Innogenetics HCV Genotyping Patent
  • GE Healthcare Takes Over Clarient
  • Cypress to Sell Diagnostics Unit to Exagen
  • EB Analytics Acquires EnviroLogix
  • IRIS Takes over AlliedPath
  • bioMerieux Takes Over Selected Assets of AnagnosTec
  • Hologic Takes Over Sentinelle Medical
  • Gen-Probe Takes Over GTI Diagnostics
  • LabCorp Takes Over Genzyme Genetics
  • bioMerieux Inks Agreement with Biocartis
  • Genzyme Sells Genzyme Genetics to LabCorp
  • Life Technologies Obtains IVD Marking for 7500 Fast Dx PCR Instrument
  • Xenomics Changes Name to TrovaGene
  • Abbott and GSK Team Up in the Area of Molecular Diagnosis
  • Asuragen Enters Into Collaborations for Pancreatic Cancer Tests
  • Transgenomic Licenses Intellectual Property from Integragen
  • Health Discovery Inks Agreement with Pancreas, Biliary and Liver Surgery Center of New York
  • Qiagen Enters into Agreement with Celera
  • The Tecan Group Inks Agreement with Enigma
  • Northeast Pharmaceuticals to Establish Biopharma JV with Shenyang
  • Wescor Divests Microarray Technology Related Assets to Gamida For Life Group
  • Predictive Biosciences Takes Over OncoDiagnostic Laboratory
  • Applied Biosystems Obtains Approval for AmpF?STR(r) MiniFiler(tm) PCR Amplification Kit
  • Life Technologies Acquires AcroMetrix
  • Ipsogen SA and The Institut Curie Enters into Scientific Collaboration Agreement
  • bioTheranostics and Ferrer inCode Enters into Commercial Agreement
  • Quidel Corp Signs Definitive Agreement to Purchase Diagnostic Hybrids
  • Abbott Obtains CE Marking for New Diagnostic Test
  • Transgenomic Enters into Licensing Agreement with Gene Solutions
  • QIAGEN Acquires SABiosciences
  • Corgenix Medical and BG Medicine Inks Supply Agreement
  • Roche receives FDA Approval for Additional Usage of cobas(r) TaqScreen MPX Test
  • Gen-Probe Obtains FDA Approval for Marketing of ProParaflu+TM Assay
  • bioMerieux Enters into Agreement with GSK
  • Tecan Group and Hologic Sign Agreement
  • QIAGEN Takes Over DxS
  • Tyrian Ends Partnership with Becton, Dickinson and Co
  • Becton, Dickinson and Co to Purchase HandyLab
  • Quidel and BioHelix Enter into Agreement
  • Gen-Probe to Take Over Prodesse
  • Summit Partners Acquires Stake in ApoCell
  • Merck to form Alliance with QIAGEN
  • Gen-Probe to Spin Off Industrial Testing Assets
  • ImClone Systems and Bristol-Myers Squibb Enter into Collaboration with DxS
  • Danaher to Acquire A Joint Venture Company
  • Abbott Enters into Alliance with Pfizer for Molecular Diagnostic Test
  • Rosetta and Warnex Ink Distribution Agreement
  • ViraCor Laboratories Merges with IBT Laboratories
  • ELITech Takes Over Assets of Nanogen
  • LabCorp Signs Definitive Agreement with Monogram Biosciences
  • Axial Biotech and University of Utah Enter into Collaboration
  • Celera and Bayer Schering Pharma Sign Licensing Agreement
  • AVESTHAGEN Enters into Collaboration with VTT Technical Research Centre
  • 3M Terminates Collaboration Agreement with Gen-Probe
  • BioGenex and Abbott Expand Joint Development and Distribution Agreement
  • Pfizer Extends Collaboration Agreement with Monogram Biosciences
  • BD Diagnostics Inks Agreement with HandyLab
  • TriLink BioTechnologies and Osmetech Molecular Diagnostics Ink Agreement
  • PerkinElmer Buys Analytica of Branford
  • Ipsogen Signs Agreement with Arup Laboratories
  • Prometheus Laboratories and Rosetta Genomics Ink Agreement
  • AMDL and Precision Diagnostic Laboratory Signs Agreement
  • Osmetech Signs Agreement with Fisher HealthCare
  • Interleukin Genetics Inks Licensing Agreement with LABEC Pharma
  • deCODE Genetics Inks Licensing Agreements with Celera
  • Nuvera Biosciences Signs Licensing Agreement with Veridex
  • GE Healthcare Inks Research Agreement with Brigham and Women's Hospital
  • Gen-Probe Purchases Tepnel Life Sciences
  • AdnaGen AG Receives US Patent
  • Agilent Technologies Selects Asuragen as Certified Service Provider
  • Genstruct Enters into Partnership with Gene Logic
  • Lab21 Takes Over Biotec Laboratories
  • ProGenTech and Innovative Biosensors Jointly Sign Extension Agreement
  • Nanogen Signs and Scandinavian Gene Synthesis Inks Agreement
  • Health Discovery Corporation Inks Licensing Agreement with Abbott
  • BD Diagnostics Receives CE Marking for Amplified DNA Assays
  • Transgenomic Signs Licensing Agreement Power3 Medical Products
  • Rubicon Genomics and Abbott Enter into Licensing Agreement
  • Novartis Extends Collaboration with Gen-Probe
  • Eurogentec Receives ISO-Certification for IVD Oligonucleotides
  • Dako and OSI Pharmaceuticals Enter into Collaboration
  • Combimatrix Molecular Diagnostics and Lenetix Enter into Partnership
  • Sequenom to Acquire AttoSense(tm) Tests of SensiGen
  • Epigenomics AG and Sysmex Ink Research and Development Collaboration Deal
  • Gene Express and Biogenuix Medsystems Signs Distribution Agreement
  • Gene Express and Funakoshi Enter into Distribution Agreement
  • BD and Company Obtains FDA Approval for Marketing GeneOhm(tm) Cdiff Test
  • XDx and Bristol-Myers Squibb Company Signs Collaborative Agreement
  • Rosetta Genomics and Teva Pharmaceutical Industries Signs Distribution Agreement

9. PRODUCT DEVELOPMENTS/ INTRODUCTIONS

  • Quest Diagnostics Introduces Cervical Cancer TERC Test
  • BD Diagnostics Introduces Range of Open System Extraction and Master Mix Kits
  • Pro-Lab Diagnostics Launches Portrait Analyser
  • Quest Diagnostics Introduces Molecular Tests for Thyroid Cancer
  • Seegene to Launch Quantitative TOCE Highly Multiplexed Quantitative Real-Time Molecular Technology
  • ELITech Molecular Diagnostics Unveils 2nd Generation MRSA/SA ELITe MGB(r) Kit
  • MDxHealth Introduces ConfirmMDx(tm) for Prostate Cancer Test
  • Ipsos Healthcare Unveils Molecular Diagnostic Monitor Line
  • Seegene Launches Anyplex(tm) MDR-TB Test
  • Berg Diagnostics Introduces Molecular Diagnostics Offerings
  • Life Technologies Unveils VetMAX(tm)-Gold SIV Detection Kit
  • Life Technologies Obtains Chinese Approval for Applied Biosystems 3500 Dx / 3500xL Dx Genetic Analyzer
  • LabCorp Launches HCV GenoSure NS3/4A
  • Quest Diagnostics Launches AccuType IL28B Test
  • Quest Diagnostics Unveils Simplexa(tm) Direct Test
  • Quest Diagnostics Unveils Simplexa(tm) Dengue Test

10. PRODUCT LAUNCHES IN RECENT PAST - A PERSPECTIVE BUILDER

  • Quest Diagnostics Unveils Molecular Blood Test
  • LabCorp Unveils IL-28B Test
  • Gen-Probe Unveils ELUCIGENE(tm) KRAS.BRAF Kit
  • QIAGEN Unveils QIAsymphony RGQ System
  • Gen-Probe Unveils PANTHER(tm) System
  • Life Technologies Unveils ViralSEQ(tm) Vesivirus Detection Kit
  • Applied Biosystems New Forensic DNA Kits
  • Quest Diagnostics Launches ColoVantage(tm) Test
  • QIAGEN Introduces CE-labeled KRAS Kit
  • Roche Introduces Cobas 4800
  • bioMerieux Launches Upgraded Version of NucliSENS EasyQ(r) Influenza A/B Test
  • bioMerieux Introduces NucliSENS EasyQ(r) MRSA
  • Roche Launches AMPLILINK 3.3 Series Software and cobas p 630 Instrument
  • Applied Biosystems Unveils 3500 Series and 3500 DX Series Genetic Analyzer
  • Prometheus Laboratories Introduces New Range of Cancer Diagnostic Products
  • Sequenom Introduces SensiGene Cystic Fibrosis Carrier Screening Test
  • Triplex and MedMira to Unveil New Rapid Tests
  • Applied Biosystems to Introduce New Range of TaqMan(r) PCR Assays
  • Quest Diagnostics Unveils HIV-1 Coreceptor Tropism Test
  • Luminex introduced New Range of Cystic Fibrosis Tests
  • bioMerieux Introduces VIDAS(r) EBV Test
  • Luminex Unveils Two Novel Cystic Fibrosis Tests
  • MEDomics Launches MitoDx(tm) for Diagnosing Mitochondrial Diseases
  • Exagen Diagnostics Unveils eXaIBStest and eXaIBD Blood Tests
  • bioMerieux Introduces NucliSENS EasyQ(r) HIV-1 v2.0 Test
  • PreAnalytiX Introduces PAXgene(r) Blood miRNA Kit
  • ViraCor Laboratories Introduces New JCV Test
  • ViraCor Laboratories Rolls Out JC Virus Detection Test
  • Focus Diagnostics Laboratory Introduces PCR Test
  • Siemens Launches CLINITEK AUWi Urine Analyzing System
  • Ocimum Biosolutions to Introduce New H1N1 Virus Detection Test
  • Myriad Genetics Introduces OnDose for Cancer Diagnosis
  • Applied Biosystems Introduces TaqMan(r) Array Gene Signature Plates
  • GeneNews to Develop Blood-Based Diagnostic Tests
  • Seegene Rolls Out Seeplex(r) Diarrhea ACE Detection Test
  • Seegene Unveils Seeplex(r) Meningitis ACE Detection test
  • Cepheid Introduces Xpert MRSA/SA Nasal Diagnostic Test
  • Roche to Launch LightCycler Test
  • Xenomics Unveils New Technology for Analyzing in Vivo Cell Death
  • bioMerieux Unveils NucliSENS EasyQ(r) HPV Molecular Analytical Test
  • Xenomics to Introduce Innovative Gender Prediction Test
  • Evogen Unveils New EvoCycler(tm) HD12 Molecular Diagnostics System
  • Siemens Healthcare Launches Innovance Antithrombin Test
  • Rosetta Genomics Launches miRview(tm) meso Diagnostic Test
  • ViraCor Laboratories Introduces Cytomegalovirus Antiviral Resistance Test
  • Abbott Launches Diagnostic Test for HPV Detection
  • Pathwork Diagnostics Introduces Tissue of Origin Test
  • Evogen to Offer Diagnostic Tests

11. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Laboratories (US)
  • Abbott Molecular (US)
  • Life Technologies Corporation (US)
  • Celera (US)
  • bioMerieux (France)
  • CytoCore Inc. (US)
  • ELITech Group (France)
  • GE Healthcare (US)
  • Genzyme Corp. (US)
  • Hologic, Inc. (US)
  • Laboratory Corporation of America(r) Holdings (US)
  • MiraiBio, Inc. (US)
  • Novartis Diagnostics (US)
  • QIAGEN N.V (The Netherlands)
  • Quest Diagnostics, Inc. (US)
  • Roche Diagnostics (Switzerland)
  • Siemens Healthcare Diagnostics Inc. (US)
  • Tecan Group Ltd. (Switzerland)

12. GLOBAL MARKET PERSPECTIVE

    • Table 4: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 5: World Historic Review for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 6: World 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)
  • Molecular Diagnostics Market by Application
    • Table 7: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 8: World Historic Review for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 9: World 15-Year Perspective for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)
    • Table 10: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 11: World Historic Review for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - The US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 12: World 15-Year Perspective for Molecular Diagnostics (Pharmacogenomics) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)
    • Table 13: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Cancer Screening) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Molecular Diagnostics (Cancer Screening) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 15: World 15-Year Perspective for Molecular Diagnostics (Cancer Screening) by Geographic Region - Percentage Breakdown of Dollar Sales for the US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current and Future Analysis
    • A Precursor to the Molecular Diagnostics Market in the US
    • US Diagnostic Market: An Overview
    • Molecular Diagnostics Heavily Tied to Proteomics and Genomics
    • Burgeoning Potential for Genetic Testing
    • Regulatory Environment
    • Regulations Out for Molecular Diagnostic Testing of HPV
    • Limited Reimbursements - A Major Hindrance
    • Strategic Corporate Developments
    • Product Launches
    • Key players
  • B. Market Analytics
    • Table 16: US Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 17: US Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 18: US 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 19: Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 20: Canadian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 21: Canadian 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
  • B. Market Analytics
    • Table 22: Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 23: Japanese Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 24: Japanese 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Insight into Molecular Diagnostics Markets in Europe
    • Table 25: European IVD Market for Select Countries (2010) - Market Value in US$ Million for Spain, UK, Germany, Italy, France, Poland, Netherlands, Belgium, Denmark, Portugal, Austria, Sweden, Bulgaria and Lithuania (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 26: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 27: European Historic Review for Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 28: European 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)
    • Table 29: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 30: European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 31: European 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Developments
    • Product Launch
    • Key players
  • B. Market Analytics
    • Table 32: French Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 33: French Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 34: French 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current and Future Analysis
    • Overview
    • Table 35: German Market for Laboratory Product (2010) - Market Value (in US$ Million) and Percentage Share for Clinical Chemistry Reagents, Immunochemistry Reagents, Hematology, Infectious Immunology, Consumables/Instruments, Microbiology Reagents and Services/Spare Parts (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 36: German Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 37: German Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 38: German 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Current and Future Analysis
  • B. Market Analytics
    • Table 39: Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 40: Italian Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 41: Italian 15Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
    • Product Launch
  • B. Market Analytics
    • Table 42: The UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 43: The UK Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 44: The UK 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)

4e. REST OF EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Developments
    • Product Launches
    • Key players
  • B. Market Analytics
    • Table 45: Rest of European Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 46: Rest of European Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 47: Rest of European 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2004, 2011 and 2018 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current and Future Analysis
    • Diagnostic Market in India
    • Key Statistics
    • Table 48: Leading Players in the Chinese IVD Market (2010) - Percentage Share Breakdown of Value Sales for Roche, Beckman/Danaher, Abbott, Siemens, Symex, Mindray, Hitachi, bioMerieux, J&J, DAAN and Others (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
    • Product Launches
  • B. Market Analytics
    • Table 49: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 50: Asia-Pacific Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 51: Asia-Pacific 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Current and Future Analysis
    • Product Launches
  • B. Market Analytics
    • Table 52: Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 53: Rest of World Historic Review for Molecular Diagnostics by Application - Infectious Disease Testing, Pharmacogenomics and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 54: Rest of World 15-Year Perspective for Molecular Diagnostics by Application - Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics and Cancer Screening Markets for Years 2004, 2011 and 2018 (includes corresponding Graph/Chart)
Show More
Pricing
Get Notified
Email me when related reports are published